Current Research Studies
The Effects of Tirzepatide in Young adults with Prader-Willi Syndrome, Hypothalamic Obesity and General Non-Syndromic Obesity
Tirzepatide
What is the goal of the study?
To evaluate the percent change in weight and BMI from baseline during 48 weeks of treatment with tirzepatide in young adults with Prader-Willi Syndrome (PWS), hypothalamic obesity (HO), general non-syndromic obesity (GNSO) and obesity
Who can participate in the study?
Please contact the study team listed below to learn more.